Comparative Analysis of Ketorolac and Parecoxib for Postoperative Pain Management in Uvulopalatopharyngoplasty

Overview

Journal J Clin Med

Specialty General Medicine

Date 2024 Aug 10

PMID 39124688

Authors

Cheng-Yu Hsieh

Chuan-Hung Sun

Chung-Ching Lin

Yi-Fan Chou

Affiliations

Soon will be listed here.

Abstract

Uvulopalatopharyngoplasty (UPPP) is a prevalent surgical procedure for treating obstructive sleep apnea. Effective postoperative pain management is crucial for patient comfort and recovery. This study aimed to compare the analgesic efficacies of parecoxib and ketorolac in patients undergoing UPPP. A prospective, randomized, double-blind study was conducted on 83 patients who received either parecoxib (40 mg intravenously every 12 h) or ketorolac (30 mg intravenously every 8 h) for 2 days following UPPP. Postoperative pain and swallowing discomfort were assessed using visual analog scales (VASs) at 4, 24, 48, and 72 h. The time to resume eating and adverse reactions were also recorded. At 24 and 48 h postoperatively, the mean VAS score was significantly higher in the ketorolac group compared to the parecoxib group (5.0 ± 2.3 vs. 3.6 ± 2.2, = 0.005 and 3.9 ± 2.2 vs. 2.5 ± 1.7, < 0.001, respectively). However, no significant difference in the mean VAS scores was observed between the two groups at 72 h postoperatively. With regards to postoperative swallowing pain, the ketorolac group exhibited significantly higher mean VAS scores than the parecoxib group at 4, 24, 48, and 72 h postoperatively. Intravenous parecoxib may offer superior analgesic benefits in the early postoperative period, particularly in alleviating swallowing pain, compared to ketorolac in UPPP procedures.

References

Cheer S, Goa K . Parecoxib (parecoxib sodium). Drugs. 2001; 61(8):1133-41; discussion 1142-3. DOI: 10.2165/00003495-200161080-00010. View

Gan T . Poorly controlled postoperative pain: prevalence, consequences, and prevention. J Pain Res. 2017; 10:2287-2298. PMC: 5626380. DOI: 10.2147/JPR.S144066. View

Hawkey C . Cyclooxygenase inhibition: between the devil and the deep blue sea. Gut. 2002; 50 Suppl 3:III25-30. PMC: 1867681. DOI: 10.1136/gut.50.suppl_3.iii25. View

Ibrahim A, Feldman J, Karim A, Kharasch E . Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. Anesthesiology. 2003; 98(4):853-61. DOI: 10.1097/00000542-200304000-00011. View

Smith C, Zhang Y, Koboldt C, Muhammad J, Zweifel B, Shaffer A . Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci U S A. 1998; 95(22):13313-8. PMC: 23795. DOI: 10.1073/pnas.95.22.13313. View

Xie G, Chu Q, Liu C . Application of parecoxib in post-uvulopalatopharyngoplasty analgesia. J Int Med Res. 2013; 41(5):1699-704. DOI: 10.1177/0300060513489473. View

Philip Malan Jr T, Gordon S, Hubbard R, Snabes M . The cyclooxygenase-2-specific inhibitor parecoxib sodium is as effective as 12 mg of morphine administered intramuscularly for treating pain after gynecologic laparotomy surgery. Anesth Analg. 2005; 100(2):454-460. DOI: 10.1213/01.ANE.0000143355.52418.CF. View

Franklin K, Anttila H, Axelsson S, Gislason T, Maasilta P, Myhre K . Effects and side-effects of surgery for snoring and obstructive sleep apnea--a systematic review. Sleep. 2009; 32(1):27-36. PMC: 2625321. View

Cozowicz C, Chung F, Doufas A, Nagappa M, Memtsoudis S . Opioids for Acute Pain Management in Patients With Obstructive Sleep Apnea: A Systematic Review. Anesth Analg. 2018; 127(4):988-1001. DOI: 10.1213/ANE.0000000000003549. View

10.

Stoltz R, Harris S, Kuss M, Lecomte D, Talwalker S, Dhadda S . Upper GI mucosal effects of parecoxib sodium in healthy elderly subjects. Am J Gastroenterol. 2002; 97(1):65-71. DOI: 10.1111/j.1572-0241.2002.05265.x. View

11.

Lynn Rasmussen G, Steckner K, Hogue C, Torri S, Hubbard R . Intravenous parecoxib sodium foracute pain after orthopedic knee surgery. Am J Orthop (Belle Mead NJ). 2002; 31(6):336-43. View

12.

Hollis L, Burton M, MILLAR J . Perioperative local anaesthesia for reducing pain following tonsillectomy. Cochrane Database Syst Rev. 2000; (2):CD001874. PMC: 7025437. DOI: 10.1002/14651858.CD001874. View

13.

Ibrahim A, Karim A, Feldman J, Kharasch E . The influence of parecoxib, a parenteral cyclooxygenase-2 specific inhibitor, on the pharmacokinetics and clinical effects of midazolam. Anesth Analg. 2002; 95(3):667-73, table of contents. DOI: 10.1097/00000539-200209000-00032. View

14.

McClain K, Williams A, Yaremchuk K . Ketorolac usage in tonsillectomy and uvulopalatopharyngoplasty patients. Laryngoscope. 2019; 130(4):876-879. DOI: 10.1002/lary.28077. View

15.

Nussmeier N, Whelton A, Brown M, Joshi G, Langford R, Singla N . Safety and efficacy of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib after noncardiac surgery. Anesthesiology. 2006; 104(3):518-26. DOI: 10.1097/00000542-200603000-00020. View

16.

Nikanne E, Virtaniemi J, Aho M, Kokki H . Ketoprofen for postoperative pain after uvulopalatopharyngoplasty and tonsillectomy: two-week follow-up study. Otolaryngol Head Neck Surg. 2003; 129(5):577-81. DOI: 10.1016/S0194-59980301579-1. View

17.

Rajakariar R, Yaqoob M, Gilroy D . COX-2 in inflammation and resolution. Mol Interv. 2006; 6(4):199-207. DOI: 10.1124/mi.6.4.6. View

18.

Hsieh C, Hsu C, Wu H, Sun C . Comparison Benefit between Hydrogen Peroxide and Adrenaline in Tonsillectomy: A Randomized Controlled Study. J Clin Med. 2022; 11(10). PMC: 9145324. DOI: 10.3390/jcm11102723. View

19.

Philip Malan Jr T, Marsh G, Hakki S, Grossman E, Traylor L, Hubbard R . Parecoxib sodium, a parenteral cyclooxygenase 2 selective inhibitor, improves morphine analgesia and is opioid-sparing following total hip arthroplasty. Anesthesiology. 2003; 98(4):950-6. DOI: 10.1097/00000542-200304000-00023. View